The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CLVSF | -16.68% | -52.98% | -13.94% | +771% |
| S&P | +13.95% | +78.35% | +12.25% | +535% |
CellaVision AB engages in the provision of automated microscopy systems in the field of hematology. It operates through the following geographical segments: Americas; APAC; and EMEA. The firm's products include DM1200; DM9600; DC-1; Peripheral Blood Application; Advanced RBC Application; and Server Software. The company was founded by Lars Christer Fedrik Fåhraeus on November 16, 1994 and is headquartered in Lund, Sweden.
No news articles found for CellaVision Ab (publ).
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $20.96M | 21.1% |
| Gross Profit | $14.01M | 16.9% |
| Gross Margin | 66.83% | -2.4% |
| Market Cap | $401.33M | -15.5% |
| Market Cap / Employee | $1.70M | 0.0% |
| Employees | 236 | 0.0% |
| Net Income | $4.53M | 19.3% |
| EBITDA | $6.75M | 23.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $20.42M | 51.0% |
| Accounts Receivable | $13.05M | 40.3% |
| Inventory | 12.1 | 7.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.30M | 13.2% |
| Short Term Debt | $1.48M | 15.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 14.83% | 0.4% |
| Return On Invested Capital | 17.57% | -0.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $3.65M | 8.7% |
| Operating Free Cash Flow | $5.65M | 49.5% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 27.77 | 31.24 | 29.43 | 26.07 | -26.24% |
| Price to Book | 6.23 | 5.51 | 5.33 | 4.43 | -29.29% |
| Price to Sales | 5.64 | 6.28 | 5.93 | 5.25 | -23.52% |
| Price to Tangible Book Value | 15.49 | 13.28 | 14.15 | 11.45 | -28.62% |
| Price to Free Cash Flow TTM | 32.87 | 32.06 | 45.45 | 38.12 | - |
| Enterprise Value to EBITDA | 61.14 | 71.61 | 80.95 | 57.68 | -31.21% |
| Free Cash Flow Yield | 3.0% | 3.1% | 2.2% | 2.6% | - |
| Return on Equity | 18.5% | 18.7% | 17.9% | 18.3% | 0.04% |
| Total Debt | $2.29M | $3.16M | $2.90M | $2.78M | 14.51% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
